Your session is about to expire
← Back to Search
Virus Therapy
VIR-2482 (Dose 1) for Flu
Phase 2
Waitlist Available
Research Sponsored by Vir Biotechnology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 26 weeks
Awards & highlights
Summary
This trial is testing VIR-2482, a new treatment aimed at preventing the flu (influenza A). It focuses on healthy adults aged 18 to less than 65 years who do not have risk factors for serious flu complications. The treatment likely works by boosting the immune system or directly fighting the flu virus.
Eligible Conditions
- Flu
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 26 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 26 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With Adverse Events of Special Interest (AESI)
Number of Participants With Clinical Laboratory Abnormalities
Number of Participants With Solicited Injection Site Reactions
+3 moreSecondary study objectives
Percentage of Participants With CDC-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])
Percentage of Participants With WHO-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: VIR-2482 (Dose 2)Experimental Treatment1 Intervention
Group II: VIR-2482 (Dose 1)Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Vir Biotechnology, Inc.Lead Sponsor
29 Previous Clinical Trials
10,297 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are between the ages of 18 and 65 years.You have taken any experimental medication within the last 90 days or within 5 half-lives of that medication.You have a medical history or symptoms that put you at a high risk of developing complications from the flu.You have a fever and may or may not have respiratory symptoms.You had a serious allergic reaction in the past that caused hives, swelling, or difficulty breathing.
Research Study Groups:
This trial has the following groups:- Group 1: VIR-2482 (Dose 1)
- Group 2: Placebo
- Group 3: VIR-2482 (Dose 2)
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger